share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

Recursion Pharmaceuticals | 4:持股变动声明-高管 Secora Michael
美股SEC公告 ·  06/17 17:50
Moomoo AI 已提取核心信息
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock on June 13 and June 14, 2024. Secora acquired a total of 78,750 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 30,000 shares in the open market, with sale prices ranging from $9.2721 to $9.3199 per share, resulting in a total market value of $278,880 for the disposed shares. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amount to 1,267,843 shares of Class A Common Stock.
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock on June 13 and June 14, 2024. Secora acquired a total of 78,750 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 30,000 shares in the open market, with sale prices ranging from $9.2721 to $9.3199 per share, resulting in a total market value of $278,880 for the disposed shares. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amount to 1,267,843 shares of Class A Common Stock.
致富金融(临时代码)的首席财务官迈克尔·塞科拉(Michael Secora)于2024年6月13日和6月14日完成了一系列关于该公司A类普通股的交易。塞科拉通过行权衍生证券以每股2.22美元的价格买入了总共78,750股股票。同时,他在公开市场上卖出了30,000股股票,售价在9.2721到9.3199美元之间,因而出售的股票的总市值为278,880美元。在这些交易之后,塞科拉直接持有致富金融的1,267,843股A类普通股。
致富金融(临时代码)的首席财务官迈克尔·塞科拉(Michael Secora)于2024年6月13日和6月14日完成了一系列关于该公司A类普通股的交易。塞科拉通过行权衍生证券以每股2.22美元的价格买入了总共78,750股股票。同时,他在公开市场上卖出了30,000股股票,售价在9.2721到9.3199美元之间,因而出售的股票的总市值为278,880美元。在这些交易之后,塞科拉直接持有致富金融的1,267,843股A类普通股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息